(1554032) Bendamustine, Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Updated Results of the CLL2-BAAG Trial of the German CLL Study Group (GCLLSG)

Primary Author; Presenting Author(s)

• 

  Paula Cramer, MD

  Faculty of Medicine and University Hospital Cologne
  Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne
  Cologne, Germany

  Slides

Co-Author(s)

• 

  Moritz Fürstenau, MD

  Faculty of Medicine and University Hospital Cologne
  Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne
  Cologne, Germany
• SR

  Sandra Robrecht, PhD

  Faculty of Medicine and University Hospital Cologne
  Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne
  Cologne, Germany
• AG

  Adam Giza, MSc

  ST
  Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne and Duesseldorf, German CLL Study Group, Faculty of Medicine and University Hospital Cologne, University of Cologne
  Cologne, Germany
• AF

  Anna Fink, MD

  Faculty of Medicine and University Hospital Cologne
  Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne
  Cologne, Germany
• 

  Kirsten Fischer, MD

  Faculty of Medicine and University Hospital Cologne
  Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne
  Department I of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, University Hospital Cologne and University of Cologne
  Cologne, Germany
• 

  Petra Langerbeins, MD

  Faculty of Medicine and University Hospital Cologne
  Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne
  Cologne, Germany
• 

  Othman Al-Sawaf, MD

  Faculty of Medicine
  University Hospital Cologne
  Cologne, Germany
• 

  Eugen Tausch, MD

  Treating physician and research fellow
  Department of Internal Medicine III, Ulm University
  Ulm, Germany
• CS

  Christof Schneider, MD

  MD
  Department of Internal Medicine III, Ulm University
  Ulm, Germany
• JS

  Johannes Schetelig, Professor

  Department I of Internal Medicine, University Hospital Carl Gustav Carus, Dresden, Germany
  Dresden, Germany
• 

  Peter Dreger, MD

  CLL Program Leader
  Department V of Internal Medicine, University Hospital Heidelberg
  Heidelberg University Hospital
  Heidelberg, Germany
• SB

  Sebastian Böttcher, MD

  Clinic for Internal Medicine III (Hematology, Oncology, Palliative Care), Rostock University Medical School
  Rostock, Germany
• KK

  Karl-Anton Anton Kreuzer, Professor

  Consultant
  Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne and Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne
  Cologne, Germany
• AS

  Anke Schilhabel, N/A

  Department of Internal Medicine II, University Schleswig-Holstein
  Kiel, Germany
• MB

  Monika Brüggemann, Professor

  Department of Internal Medicine II, University Schleswig-Holstein
  Kiel, Germany
• MK

  Michael Kneba, Professor

  Department of Internal Medicine II, University Schleswig-Holstein
  Kiel, Germany
• CW

  Clemens M. Wendtner, MD

  Head physician
  Department of Hematology, Oncology, Immunology, Palliative Care, Munich Clinic Schwabing
  Munich, Germany
• 

  Stephan Stilgenbauer, MD, PhD

  Department of Internal Medicine III, Ulm University
  Ulm, Germany
• 

  Barbara Eichhorst, MD

  Associate Professor, Consultant Hematologist
  University Hospital of Cologne
  Cologne, Germany
• 

  Michael Hallek, MD

  Faculty of Medicine and University Hospital Cologne
  Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne
  Cologne, Germany